Use of Sodium Glucose Cotransporter-2 Inhibitor and Thiol Disulfide Homeostasis in Type -2 Diabetic Patients
dc.authorscopusid | 55536951000 | |
dc.authorscopusid | 60053865200 | |
dc.authorscopusid | 36642946400 | |
dc.authorscopusid | 7003566828 | |
dc.authorscopusid | 42960989200 | |
dc.contributor.author | Yildiz, Saliha | |
dc.contributor.author | Akgündüz, Mehmet Ali | |
dc.contributor.author | Neselioglu, S. | |
dc.contributor.author | Erel, Özcan | |
dc.contributor.author | Alay, Murat | |
dc.date.accessioned | 2025-09-30T16:35:30Z | |
dc.date.available | 2025-09-30T16:35:30Z | |
dc.date.issued | 2025 | |
dc.department | T.C. Van Yüzüncü Yıl Üniversitesi | en_US |
dc.department-temp | [Yildiz] Saliha, Department of Endocrinology, Van Yüzüncü Yıl Üniversitesi, Van, Turkey; [Akgündüz] Mehmet Ali, Department of Internal Diseases, Van Education and Research Hospital, Van, Turkey; [Neselioglu] S., Department of Biochemistry, Ankara Yildirim Beyazit University, Ankara, Turkey; [Erel] Özcan, Department of Biochemistry, Ankara Yildirim Beyazit University, Ankara, Turkey; [Alay] Murat, Department of Endocrinology, Van Yüzüncü Yıl Üniversitesi, Van, Turkey | en_US |
dc.description.abstract | To investigate the presence of antioxidant activity in sodium glucose cotransporter-2 inhibitors (SGLT-2I), which have a preventive effect on the progression of complications since reactive oxygen species damage has a major effect on diabetes morbidity and mortality. Thiol, disulfide and ischemia-modified albumin levels were measured in the blood of type 2 diabetes mellitus (DM) patients who were using SGLT-2I for at least one year and those who were not using this drug. Data of 53 patients using SGLT-2I and 62 patients not using SGLT-2I were analyzed. Gender and age were similar in the two groups (p: 0.293, 0.772, respectively). DM duration, HbA1c level and number of drug types used in the combination were higher in the SGLT-2I group (p: 0.003, <0.001, and <0.001, respectively). Disulfide/native thiol was significantly higher in the SGLT-2I group (4.29±1.65 vs 4.06±1.99, p: 0.038). In the analyses of the groups under 50 years of age, female gender, HbA1c≥7%, no complications and concomitant use of dipeptidyl peptidase-4 inhibitor (DPP-4I), the disulfide/native thiol ratio was significantly higher in SGLT-2I users than in non-users (p: 0.072, 0.021, 0.040, 0.008 and 0.032, respectively). In the analysis of patients with DM duration of less than 10 years, the disulfide/native thiol ratio in the SGLT-2I group was significantly higher than those who did not use the drug (p:0.048). Native thi ols were statistically similar in all group analyses (p>0.05). Again, IMA was similar in all group analyses (p>0.05) SGLT-2I use affects thiol disulfide homeostasis more especially in those younger than 50 years, with diabetes duration <10 years, without complications, HbA1c≥7% and using DPP-4I together. The fact that no decrease was detected in native thiol suggests that this effect is more in the antioxidant direction. © 2025 Elsevier B.V., All rights reserved. | en_US |
dc.identifier.doi | 10.5505/ejm.2025.27864 | |
dc.identifier.endpage | 425 | en_US |
dc.identifier.issn | 1309-3886 | |
dc.identifier.issn | 1301-0883 | |
dc.identifier.issue | 3 | en_US |
dc.identifier.scopus | 2-s2.0-105013634606 | |
dc.identifier.scopusquality | Q4 | |
dc.identifier.startpage | 417 | en_US |
dc.identifier.uri | https://doi.org/10.5505/ejm.2025.27864 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14720/28574 | |
dc.identifier.volume | 30 | en_US |
dc.identifier.wosquality | N/A | |
dc.language.iso | en | en_US |
dc.publisher | Yuzuncu Yil Universitesi Tip Fakultesi | en_US |
dc.relation.ispartof | Eastern Journal of Medicine | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Native Thiol | en_US |
dc.subject | SGLT-2i | en_US |
dc.subject | Thiol-Disulfide Homeostasis | en_US |
dc.subject | Type 2 Diabetes Mellitus | en_US |
dc.subject | Disulfide | en_US |
dc.subject | Hemoglobin A1c | en_US |
dc.subject | SPSS v28 | en_US |
dc.subject | Albumin | en_US |
dc.subject | Antidiabetic Agent | en_US |
dc.subject | Unclassified Drug | en_US |
dc.subject | Adult | en_US |
dc.subject | Aged | en_US |
dc.subject | Antioxidant Activity | en_US |
dc.subject | Article | en_US |
dc.subject | Controlled Study | en_US |
dc.subject | Disease Duration | en_US |
dc.subject | Disease Exacerbation | en_US |
dc.subject | Female | en_US |
dc.subject | Homeostasis | en_US |
dc.subject | Human | en_US |
dc.subject | Major Clinical Study | en_US |
dc.subject | Male | en_US |
dc.subject | Morbidity | en_US |
dc.subject | Mortality | en_US |
dc.subject | Non-Insulin-Dependent Diabetes Mellitus | en_US |
dc.subject | Spectrophotometry | en_US |
dc.title | Use of Sodium Glucose Cotransporter-2 Inhibitor and Thiol Disulfide Homeostasis in Type -2 Diabetic Patients | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication |